Financial Blog

Dave Ramsey Says Leaders Shouldn't Worry About Gen Z, Millennial Or Boomer Employee Expectations. 'Otherwise, You're Running A Beauty Parlor'

Entrepreneur and personal finance expert Dave Ramsey says too many business leaders are overthinking generational differences in the workplace, and it's hurting their leadership. In a recent episode of his “EntreLeadership” podcast, Ramsey responded ...

AbbVie quarterly profit drops on costs but ups 2025 outlook, dividend

American Electric Power: Growth Initiatives Could Lead To Attractive Returns

American Electric Power Company, Inc. remains a solid long-term buy with robust dividend growth & investment plans. Read more on AEP stock here.

Stocks to Watch Friday: Alphabet, Fubo, Netflix, Warner Bros.

↗️ Netflix (NFLX): The stock rose 2% in premarket trading after the company’s board approved a 10-for-one stock split to help reset its lofty stock price. Shares closed Thursday at $1,089. ↗️ Warner Bros.

AbbVie lifts full-year profit outlook amid strong psoriasis drug demand

Investing.com - AbbVie has lifted its annual profit guidance, after solid demand for the pharmaceutical group’s Skyrizi psoriasis drug helped third-quarter sales surpass estimates.

Disney Goes Dark on YouTube TV. Why the House of Mouse and Google Are Feuding.

Subscribers won't be able to watch ESPN or ABC after the two sides failed to agree a licensing deal.

Pfizer Faces Off With Novo Nordisk Over Metsera Bid

U.S. drugmaker may leverage political ties as takeover battle intensifies

Analyst Says She Likes Meta Platforms (META) Valuation Amid ‘Decade of Efficiency’

We recently published 10 Stocks Moving on Buzzing News as Analyst Issues Strong Warning About AI Valuations. Meta Platforms, Inc. (NASDAQ:META) is one of the stocks moving on buzzing news. Stephanie Link, the Chief Investment Strategist, Head of Investment Solutions and Portfolio Manager at Hightower Advisors, said in a recent program on CNBC that she […]

AbbVie Beats Third-Quarter Forecasts As Immunology Kingpin Grows 47%

AbbVie dipped early Friday, though the drug giant easily beat third-quarter forecasts on the back of its immunology meds.

AbbVie Beats Third-Quarter Estimates. There’s More to the Drugmaker’s Earnings.

FEATURE AbbVie stock traded slightly lower Friday as the biopharmaceutical giant reported mixed results across its drug portfolios in the third quarter. Adjusted earnings of $1.86 a share topped the $1.